Literature DB >> 18609128

ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis.

John W Haukeland1, Linn T Schreiner, Inger Lorgen, Svein-Oskar Frigstad, Christina Bang, Nils Raknerud, Zbigniew Konopski.   

Abstract

OBJECTIVE: The aspartate amino transferase/alanine amino transferase (ASAT/ALAT) ratio is increased in cirrhosis. Some studies indicate that the ratio may provide prognostic information as well. The purpose of this study was to further elucidate the role of the ASAT/ALAT ratio as a predictor of survival by assessing it together with classical risk factors such as age, gender and Child-Pugh (CP) class in a mixed cohort of patients with cirrhosis.
MATERIAL AND METHODS: Eighty-nine patients with alcoholic cirrhosis and 81 patients with non-alcoholic cirrhosis treated at Aker University Hospital between 1999 and 2004 were identified retrospectively. Survival data from these patients per August 2006 were retrieved from the Norwegian Death Registry. Clinical and biochemical data at time of diagnosis were assessed as predictors of survival using the Kaplan-Meier method and Cox regression models.
RESULTS: Median ASAT/ALAT ratio was significantly higher in alcoholic cirrhosis (2.42) as compared with non-alcoholic cirrhosis (1.42). In both groups, a ratio above the median was predictive of poor outcome, p=0.024 and p=0.032, respectively. Other significant predictors of death were CP class (p<0.001), clinical decompensation (p<0.001) and age (p=0.001). Cox regression analyses showed that the ASAT/ALAT ratio was a predictor of death independently of CP class, gender and age in non-alcoholic, but not in alcoholic cirrhosis. The estimated increased hazard (risk of dying) in non-alcoholic cirrhosis was 5% (CI: 1-8%) per 0.10 increase in ASAT/ALAT ratio.
CONCLUSIONS: A high ASAT/ALAT ratio is associated with increased mortality in cirrhosis. In non-alcoholic patients the ratio may provide prognostic information independently of classical risk factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18609128     DOI: 10.1080/00365520802158614

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

1.  Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity.

Authors:  Christopher Koh; Sasan Sakiani; Pallavi Surana; Xiongce Zhao; Jason Eccleston; David E Kleiner; David Herion; T Jake Liang; Jay H Hoofnagle; Milica Chernick; Theo Heller
Journal:  Hepatology       Date:  2017-06-26       Impact factor: 17.425

2.  Noninvasive markers for staging fibrosis in chronic delta hepatitis.

Authors:  V Takyar; P Surana; D E Kleiner; K Wilkins; J H Hoofnagle; T J Liang; T Heller; C Koh
Journal:  Aliment Pharmacol Ther       Date:  2016-11-04       Impact factor: 8.171

3.  Analysis of relationship of hormonal, hematological and biochemical parameters in Indian alcoholics with severity of alcohol dependence.

Authors:  Prateek Yadav; Bhupendra Yadav; Barun K Chakrabarty; Mukul Bajpai; V V Gantait; Sojan Baby; Vimal Upreti; P Ganguli
Journal:  Med J Armed Forces India       Date:  2021-08-17

4.  Biochemical Evaluation of Patients of Alcoholic Liver Disease and Non-alcoholic Liver Disease.

Authors:  Prasad P Torkadi; I C Apte; A K Bhute
Journal:  Indian J Clin Biochem       Date:  2013-02-16

Review 5.  Non-invasive markers for hepatic fibrosis.

Authors:  Ancha Baranova; Priyanka Lal; Aybike Birerdinc; Zobair M Younossi
Journal:  BMC Gastroenterol       Date:  2011-08-17       Impact factor: 3.067

Review 6.  Non-invasive assessment of liver fibrosis.

Authors:  Vasilios Papastergiou; Emmanuel Tsochatzis; Andrew K Burroughs
Journal:  Ann Gastroenterol       Date:  2012

7.  Gender and Obesity Specific MicroRNA Expression in Adipose Tissue from Lean and Obese Pigs.

Authors:  Caroline M Junker Mentzel; Christian Anthon; Mette J Jacobsen; Peter Karlskov-Mortensen; Camilla S Bruun; Claus B Jørgensen; Jan Gorodkin; Susanna Cirera; Merete Fredholm
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

8.  Attrition of Hepatic Damage Inflicted by Angiotensin II with α-Tocopherol and β-Carotene in Experimental Apolipoprotein E Knock-out Mice.

Authors:  Kaliappan Gopal; Munusamy Gowtham; Singh Sachin; Mani Ravishankar Ram; Esaki M Shankar; Tunku Kamarul
Journal:  Sci Rep       Date:  2015-12-16       Impact factor: 4.379

9.  Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease.

Authors:  Fares Ayoub; Cesar Trillo-Alvarez; Giuseppe Morelli; Jorge Lascano
Journal:  World J Hepatol       Date:  2018-01-27

Review 10.  Potential role of noninvasive biomarkers during liver fibrosis.

Authors:  Navneet Kaur; Gitanjali Goyal; Ravinder Garg; Chaitanya Tapasvi; Sonia Chawla; Rajneet Kaur
Journal:  World J Hepatol       Date:  2021-12-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.